molecular-diagnostics
Can Cas3 power a COVID/flu POCT?
Open access · cc by · source: Europe PMC
CONAN uses type I CRISPR-Cas3 collateral ssDNA cleavage for rapid (~40 min), low-cost, instrument-free SARS-CoV-2 detection and IAV single-base discrimination.
Key findings
CONAN detected SARS-CoV-2 in clinical samples and specifically resolved single-base-pair mutations in IAV variants, positioning Cas3 alongside Cas12 DETECTR and Cas13 SHERLOCK as a CRISPR-dx option for hospital POCT.
Methodology
Demonstrated target-activated nonspecific ssDNA cleavage by E. coli type I CRISPR-Cas3, then built CONAN combined with isothermal amplification for instrument-free readout on SARS-CoV-2 and influenza targets.
Limitations
Not a large multi-site regulatory trial; real-world sensitivity/specificity vs PCR across variants still need broader clinical evaluation.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Not yet placed on a claim. This paper has study layers, but no concept page yet cites it as support, challenge, or qualifier.
Related papers in this topic
Same topic cluster — not a recommendation engine.